Suvratoxumab (INN;[1] development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.
This drug was developed by MedImmune[2] This monoclonal antibody–related article is a stub.
You can help Wikipedia by expanding it.